Home › NDC Lookup › Ingredients › Dolutegravir Sodium › 49702-0228-13
⚪image loading
(from DailyMed)

Tivicay dolutegravir sodium 50 mg Tablet, Film Coated, 30-count — NDC 49702-228-13 (Billing 49702-0228-13)

by ViiV Healthcare Company · 30 TABLET, FILM COATED in 1 BOTTLE

This is a package of 30 tablets of Tivicay dolutegravir sodium 50 mg Tablet, Film Coated from ViiV Healthcare Company, marketed since Aug 2013 and currently FDA-listed; retail pharmacies pay about $77.64 per tablet (NADAC). It is this product's only package size.

NDC 49702-0228-13
🏷️ FDA NDC (as labeled) 49702-228-13 billing pads the product segment with a zero
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 49702-228-13 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
49702 labeler · 228 product · 13 package
Package marketed since
Aug 13, 2013
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
30 EA per package
Barcode (UPC-A, from the NDC)
3 4970222813 9
Medicaid fills, this package
88,570 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026
Past resolved recalls for this product (2)
Class III · May 17, 2024 · Terminated — Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR. (GlaxoSmithKline LLC) · FDA recall D-0544-2024
Class III · May 13, 2022 · Terminated — Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026. (GlaxoSmithKline LLC) · FDA recall D-0896-2022

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 49702-228-13
Product NDC 49702-228
11-digit billing NDC 49702022813
NCPDP billing unit EA — each (per item)
Application # NDA204790
SPL Set ID 5037ffdb-75d0-4abb-bd21-0a1b5920042f
Established class (EPC) Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
Mechanism of action HIV Integrase Inhibitors; Multidrug and Toxin Extrusion Transporter 1 Inhibitors; Organic Cation Transporter 2 Inhibitors
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2013-08-13
Route ORAL
Dosage form TABLET, FILM COATED
Substance DOLUTEGRAVIR SODIUM

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 071322
GCN 35079
HICL code 040533
Ingredient (HICL) Dolutegravir Sodium
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W5
Therapeutic class — intermediate (HIC2) Antiviral Agents
HIC3 code W5U
Therapeutic class — specific (HIC3) Antivirals,Hiv-1 Integrase Strand Transfer Inhibtr
AHFS code 08:18.08.12
AHFS class Hiv Integrase Inhibitor Antiretrovirals
FDB label name TIVICAY 50 MG TABLET
FDB brand name Tivicay
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 071322
  • GCN: 35079
  • HICL (First Databank): 040533
  • AHFS class code: 08:18.08.12
Why two NDCs? The FDA registers this code as 49702-228-13 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 49702-0228-13. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name TIVICAY 50 MG TABLET Ingredient Dolutegravir Sodium
📗 Our plain-language guide HelloPharmacist
  • It treats HIV-1 infection and is always used with other HIV medicines. Tivicay can also be paired with rilpivirine as a complete regimen for certain adults whose HIV is already con...
  • No. You can take it with or without food. Just follow the schedule your prescriber gave you and keep it consistent.
  • The most common ones are trouble sleeping, tiredness and headache. Call your doctor about anything that bothers you or does not go away.
  • If you get a severe rash, a rash with fever, blisters or peeling skin, facial swelling, or trouble breathing, stop the medicine and get medical help. These can be signs of a seriou...
📖 Read our full Dolutegravir guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $77.636 $2,329.07 / 30 tablets
Medicaid paysCMS SDUD · 12 mo $75.23 $2,256.98 / 30 tablets
Medicare drug plans payPart D · Q2 2026 $78.55 $2,356.59 / 30 tablets
NADAC price history (per ea) — tap or hover for the price & month
May 2021 Jan 2024 Jun 2026 Sep 2026 $77.663 $62.106
▲ Up 25% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
49702-0228-13 You're viewing this Main listing 30 TABLET, FILM COATED in 1 BOTTLE 2013-08-13 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Tivicay 50 mgthis 49702-0228-13 ViiV 30 tablets $77.636 — Availability likely —
Tivicay 50 mg 60760-0748-07 ST. 7 tablets — — FDA listed —
About this product: this is the brand-name version. We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2013
First FDA approval
Aug 2013
📍
2026
Currently FDA-listed
13 years listed
🛡️
2030
Latest patent/protection listed
not a guaranteed launch date
🔒No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route. Patent/protection dates below may affect future generic timing.

🛡️ Latest patent/protection date listed: FDA patent/protection data lists protections through Jun 2030. This may affect when a full generic version becomes widely available, but it is not a guaranteed launch date.
📅 FDA approved Aug 12, 2013 RLD RS ⏳ ~3.7 yr to latest listed protection

Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.

Patents & exclusivity — FDA Orange Book
US 8129385 — drug substance
US 8129385 — drug substance
US 9242986 — drug substance
US 9242986 — drug substance
US 8129385 — drug substance
US 9242986 — drug substance
US 8129385*PED — drug product
US 9242986*PED — drug product
US 9242986*PED — drug product
US 8129385*PED — drug product
US 9242986*PED — drug product
US 8129385*PED — drug product
2013 2015 2017 2019 2021 2023 2025 2027 2029
Today
LOE
Substance patent Formulation patent Method-of-use patent Exclusivity Pediatric +6mo
🏛️FDA exclusivity
FDA-granted marketing protection. It’s separate from patents and may be shorter than patent protection.
🧪Product / substance patents
Patents covering the active ingredient, product, formulation, or related drug features.
🎯Method-of-use patents
Patents covering specific approved uses. These can sometimes be carved out with a “skinny label,” but not always.
🛈 What do these terms mean?
Patent
Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
Substance patent
Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
Formulation (product) patent
Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
Method-of-use patent
A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
Skinny label
A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
Exclusivity
FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
Paragraph IV
A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
RLD / RS
Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
TE / AB rating
FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
LOE (loss of exclusivity)
The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.

Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.

Listed patents (12)
PatentTypeUse codeExpires
US 8129385 ↗ Drug substance — Oct 5, 2027
US 8129385 ↗ Drug substance — Oct 5, 2027
US 9242986 ↗ Drug substance — Dec 8, 2029
US 9242986 ↗ Drug substance — Dec 8, 2029
US 8129385 ↗ Drug substance — Oct 5, 2027
US 9242986 ↗ Drug substance — Dec 8, 2029
US 8129385*PED ↗ Drug product — Apr 5, 2028
US 9242986*PED ↗ Drug product — Jun 8, 2030
US 9242986*PED ↗ Drug product — Jun 8, 2030
US 8129385*PED ↗ Drug product — Apr 5, 2028
US 9242986*PED ↗ Drug product — Jun 8, 2030
US 8129385*PED ↗ Drug product — Apr 5, 2028
Common questions
Is there a generic version of TIVICAY 50 MG TABLET?
No FDA-approved generic equivalent is currently listed in the FDA Orange Book for TIVICAY 50 MG TABLET. Based on the patents and exclusivity currently listed, the Orange Book estimate is that full-label generic entry may be delayed until Jun 2030 — an estimate, not a guaranteed launch date.
The FDA approved a generic — why can’t I get it at my pharmacy yet?
FDA approval and pharmacy availability are two different things. The FDA can approve a generic years before it actually reaches pharmacies, because the brand company may still hold patents or have a settlement that delays the launch. A manufacturer also has to choose to make and sell it, and have supply ready. So a drug can be “FDA-approved generic exists” and still be brand-only at the counter today.
Why do different websites show different generic release dates?
Generic availability is not based on one single date. Some sources use the first exclusivity expiration, some use the last product patent, and others use the latest method-of-use patent. Patent challenges, settlements, licenses, and label carve-outs can also change the real-world launch date. This page shows the underlying Orange Book dates so you can see why estimates may differ.
What does “FDA listed” mean?
It means the product appears in the FDA’s official NDC directory. That’s a good sign a product exists and is intended for the U.S. market, but on its own it does not confirm a pharmacy can fill it today. Where we have recent retail pricing data (NADAC) for a product, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Orange Book for a patent or exclusivity on the brand product. It can affect when a full generic version becomes widely available — but it is not a guaranteed generic launch date. Generics sometimes arrive earlier (through a settlement or patent challenge) or later (a manufacturer still has to make and sell one).
What does “current Orange Book estimate” mean?
It means we are using the latest patent and exclusivity dates currently listed in the FDA Orange Book. It is not a guaranteed launch date.
Can a generic come out before the last patent expires?
Sometimes. A generic company may challenge a patent, settle with the brand manufacturer, receive a license, or obtain approval with a narrower label that avoids a patented use. In other cases, the last listed protection may delay full-label generic competition.
Can a generic come out after the listed dates?
Yes. Even after patents or exclusivity expire, a generic still needs FDA approval and a manufacturer must choose to market it. Supply, litigation, business decisions, or regulatory issues can delay actual availability.
What is the difference between patents and exclusivity?
Patents are legal protections usually issued by the U.S. Patent and Trademark Office. FDA exclusivity is marketing protection granted by the FDA. They are separate, and either one can affect generic timing.
Why are there multiple patent dates?
One drug can have several patents covering different things: the active ingredient, a formulation, a manufacturing process, or a specific approved use. That is why a page may show several expiration dates instead of one simple generic date.
Built from FDA Orange Book patent and exclusivity data. Dates are refreshed from public FDA data when available; the marker is max(latest patent expiry, latest exclusivity expiry). Paragraph-IV settlements and first-filer 180-day exclusivity can shift the real date; a method-of-use patent may allow an earlier skinny-label generic for non-protected indications. Generic launch timing is an estimate, not a guarantee.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Dolutegravir inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerViiV Healthcare Company
Application holderVIIV HEALTHCARE CO
FDA applicationNDA204790 (NDA)
Labeler code49702
First marketedAug 2013
Product typeHuman Prescription Drug
Portfolio26 products on file

More NDCs from ViiV Healthcare Company labeler code 49702

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
88.6K
Units reimbursed last 4 qtrs
3.1M
Gross reimbursed last 4 qtrs
$230.27M
Avg / prescription
$2,599.89
Avg / unit
$75.2328
Latest quarter Q1 2026
19.6KRx
Medicaid pays / ea
$75.2328
gross reimbursed
vs
NADAC / ea
$77.6356
acquisition cost
=
Spread
−$2.4028
-3% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
54% FFS 46% MCO
Fee-for-service · 47,427 Rx Managed care · 41,143 Rx
State Medicaid map
Alaska: 2,515 units · 343 per 100k residents AK Maine: 18,052 units · 1,294 per 100k residents ME Washington: 95,044 units · 1,217 per 100k residents WA Idaho: 390 units · 19.9 per 100k residents ID Montana: 5,987 units · 529 per 100k residents MT North Dakota: 1,470 units · 188 per 100k residents ND Minnesota: 23,635 units · 412 per 100k residents MN Wisconsin: 37,276 units · 631 per 100k residents WI Michigan: 71,156 units · 709 per 100k residents MI New York: 674,033 units · 3,444 per 100k residents NY Vermont: 1,830 units · 283 per 100k residents VT New Hampshire: 3,387 units · 242 per 100k residents NH Oregon: 31,134 units · 736 per 100k residents OR Nevada: 33,446 units · 1,047 per 100k residents NV Wyoming: no data reported WY South Dakota: 3,901 units · 424 per 100k residents SD Iowa: 13,782 units · 430 per 100k residents IA Illinois: 96,861 units · 772 per 100k residents IL Indiana: 32,055 units · 467 per 100k residents IN Ohio: 64,022 units · 543 per 100k residents OH Pennsylvania: 141,437 units · 1,091 per 100k residents PA New Jersey: 91,178 units · 981 per 100k residents NJ Massachusetts: 75,015 units · 1,071 per 100k residents MA California: 399,662 units · 1,026 per 100k residents CA Utah: 14,229 units · 416 per 100k residents UT Colorado: 30,651 units · 521 per 100k residents CO Nebraska: 8,716 units · 441 per 100k residents NE Missouri: 34,291 units · 553 per 100k residents MO Kentucky: 14,433 units · 319 per 100k residents KY West Virginia: 10,228 units · 578 per 100k residents WV Virginia: 48,945 units · 562 per 100k residents VA Maryland: 66,739 units · 1,080 per 100k residents MD Connecticut: 59,413 units · 1,643 per 100k residents CT Rhode Island: 11,527 units · 1,053 per 100k residents RI Arizona: 40,318 units · 543 per 100k residents AZ New Mexico: 10,254 units · 485 per 100k residents NM Kansas: 4,333 units · 147 per 100k residents KS Arkansas: 9,798 units · 319 per 100k residents AR Tennessee: 34,562 units · 485 per 100k residents TN North Carolina: 113,919 units · 1,051 per 100k residents NC South Carolina: 14,854 units · 276 per 100k residents SC Delaware: 13,329 units · 1,293 per 100k residents DE Oklahoma: 20,954 units · 517 per 100k residents OK Louisiana: 115,216 units · 2,519 per 100k residents LA Mississippi: 8,998 units · 306 per 100k residents MS Alabama: 36,088 units · 706 per 100k residents AL Georgia: 62,442 units · 566 per 100k residents GA D.C.: 68,627 units · 10,107 per 100k residents DC Hawaii: 5,664 units · 395 per 100k residents HI Texas: 102,452 units · 336 per 100k residents TX Florida: 120,897 units · 535 per 100k residents FL
Units reimbursed · per 100k residents
19.910,107
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 D.C. 10,107 /100k
2 New York 3,444 /100k
3 Louisiana 2,519 /100k
4 Connecticut 1,643 /100k
5 Maine 1,294 /100k
6 Delaware 1,293 /100k
7 Washington 1,217 /100k
8 Pennsylvania 1,091 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Tivicay — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Tivicay. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$146.53M
Claims incl. refills
57.4K
Beneficiaries
21.8K
Spend / beneficiary
$6,716.27
Spend / claim
$2,554.95
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 49702-0227-13 · ViiV 49702-0231-13 · ViiV →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.